TRVN News and Press, Trevena Inc. From 12/27/23

2023-12-27 09:21:21 ET More on Trevena Seeking Alpha’s Quant Rating on Trevena Historical earnings data for Trevena Financial information for Trevena For further details see: Trevena announces private placement and warrant exercise

CHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (“ Trevena ” or the “ Company ”) ( Nasdaq: TRVN ), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CN...

-- Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked nociceptive pain in a dose-related manner TRV045 selectively targets the S1P 1 receptor without associated lymphopenia ...

CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, has been awarded a national group purchasing agreement for OL...

2023-12-01 17:23:01 ET More on Trevena Trevena Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Trevena Historical earnings data for Trevena Financial information for Trevena For further details see: Trevena files for $200M ...

CHESTERBROOK, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced today the acceptance of an abstract based on the p...

2023-11-14 09:21:04 ET Trevena, Inc. (TRVN) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Barry Shin - Senior Vice President, Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Mark Demitrack - Seni...

2023-11-14 07:05:06 ET More on Trevena Seeking Alpha’s Quant Rating on Trevena Historical earnings data for Trevena Financial information for Trevena For further details see: Trevena GAAP EPS of -$0.57 misses by $0.42, revenue of $0.18M beats by $0...

Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement Company reported favorable safety and tolerability data from TRV045 POC studies Three abstracts for OLINVYK ...

Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...